The incidence of heart failure is primarily flat or declining for a presumably reflecting better
management of cardiovascular diseases, but that of heart failure with preserved ejection …

Importance In recent years, significant progress has been made in the pharmacologic
treatment of heart failure (HF) with reduced ejection fraction (HFrEF), but there is still …

HOW DID WE GET HERE? Heart failure guidelines are based around inhibition of the renin-
angiotensin and sympathetic nervous systems, two fundamental pathways which drive the …

Background—Treatments that reduce mortality and morbidity in patients with heart failure
with reduced ejection fraction, including angiotensin-converting enzyme inhibitors (ACEI) …

Clinical trials of renin-angiotensin-aldosterone system (RAAS) antagonists in heart failure
with preserved ejection fraction (HFpEF) have suggested neutral results and treatment is …

Aims A network meta‐analysis (NMA) of all recommended drug groups for the treatment of
heart failure with reduced ejection fraction (HFrEF), including their combinations, was …

Heart failure (HF) is a very common condition that, despite advances in treatment, carries
significant morbidity and mortality. Although there is good evidence for the treatment of HF …

Background Beta‐blockers and inhibitors of the renin‐angiotensin‐aldosterone system
improve survival and reduce morbidity in people with heart failure with reduced left …

Objectives This study sought to estimate and compare the aggregate treatment benefit of
pharmacological therapy for heart failure (HF) with reduced ejection fraction. Background …

Background Three drug classes (mineralocorticoid receptor antagonists [MRAs], angiotensin
receptor–neprilysin inhibitors [ARNIs], and sodium/glucose cotransporter 2 [SGLT2] …